Home › Waldenstrom Macroglobulinemia › Colorado
Waldenstrom Macroglobulinemia clinical trials in Colorado
8 studies for Waldenstrom Macroglobulinemia are looking for participants at sites in Colorado.
Cities in Colorado
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Uchealth North, Fort Collins
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Colorado Blood Cancer Institute ( Site 2726), Denver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04728893A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Colorado Denver - School of Medicine - Anschutz Medical Campus, Aurora
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
- Colorado Blood Cancer Institute (CBCI), Denver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06561347A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022SynKIR-310 for Relapsed/Refractory B-NHL
- Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.